新型肽类化合物或可干预癫痫反复发作

Core Insights - Researchers at Hebrew University of Jerusalem have developed an experimental peptide compound, TXM-CB3, which may reduce epilepsy seizures by targeting oxidative stress and inflammation associated with the condition [1][2] - Approximately 50 million people globally suffer from epilepsy, a common neurological disorder that can significantly affect patients' emotions and memory [1] - Current treatments are limited, with about 40% of patients experiencing inadequate control of seizures despite medication [1] Group 1 - TXM-CB3 belongs to the family of thioredoxin-mimetic peptides and mimics the function of natural protective proteins in the body, playing a role in regulating oxidative stress and inflammation [1] - In experiments simulating epileptic activity, TXM-CB3 reduced indicators of oxidative damage related to epilepsy and shifted immune signals from a pro-inflammatory state to a relatively protective state [1] Group 2 - Early treatment with TXM-CB3 in experimental mice delayed seizure onset and reduced seizure frequency, resulting in less damage to memory-related brain areas and improved performance in anxiety and short-term memory tests [2] - Delayed treatment after repeated seizures still provided some suppression of seizures, but improvements in cognitive and memory impairments were not significant, highlighting the importance of early intervention [2] - Further research is needed to explore the safety and efficacy of TXM-CB3 and to develop new treatment strategies aimed at enhancing the long-term quality of life for patients [2]